Jatenzo Adolescent (12-17) Safety: What Prescribers and Families Need to Know

Why Jatenzo in Adolescents Raises Distinct Safety Questions

Jatenzo received FDA approval in March 2019 for testosterone replacement in adult males with conditions causing hypogonadism. The key trial by Swerdloff et al. Enrolled men aged 18 to 65, and 87% reached eugonadal serum testosterone levels (300 to 1,100 ng/dL) by month three 1. No participants younger than 18 were included.

Off-Label Use Is Growing

Adolescent boys with confirmed hypogonadism from Klinefelter syndrome, pituitary tumors, or constitutional delay sometimes receive Jatenzo when injectable formulations cause needle-related anxiety or compliance failures. An oral capsule taken twice daily with meals offers a practical alternative. The absence of pediatric trial data, however, means clinicians rely on extrapolation from adult pharmacokinetic and safety profiles.

How Adolescent Physiology Changes the Risk Calculus

Puberty is a period of rapid bone accrual, hypothalamic-pituitary-gonadal (HPG) axis maturation, and neurodevelopmental change. Exogenous testosterone can accelerate epiphyseal fusion, suppress endogenous gonadotropin release, and alter mood regulation through androgen receptor activity in the prefrontal cortex. These mechanisms carry different weight in a 14-year-old than in a 40-year-old man with established skeletal maturity 2.

The Endocrine Society's 2018 guideline on testosterone therapy underscores that pediatric testosterone dosing should begin at 50 to 100 mg/month (injectable equivalent) and increase gradually over 3 to 4 years to mimic normal pubertal progression 2. Applying adult Jatenzo doses (237 mg twice daily) without dose titration could expose a pubertal adolescent to supraphysiologic testosterone levels.

Growth Plate and Skeletal Safety

The primary skeletal risk of any androgen therapy in adolescents is premature epiphyseal closure, which can permanently reduce adult height. Testosterone is aromatized to estradiol, and estradiol acts on growth plate chondrocytes to initiate fusion 3.

Monitoring Bone Age

A hand-wrist radiograph (Greulich-Pyle method) at baseline establishes skeletal maturity. Repeat imaging every 6 months during treatment allows clinicians to detect accelerated bone age advancement before significant height potential is lost. If bone age advances more than 1 year beyond chronological age within a 6-month treatment window, dose reduction or temporary discontinuation should be considered 2.

When to Pause Therapy

A bone age of 14 years (girls) or 16 years (boys) signals that the growth plates are nearing closure under normal conditions. In boys receiving exogenous testosterone, growth velocity may initially increase but then decelerate rapidly as fusion accelerates. Serial height measurements at each visit, plotted on sex-specific growth charts, remain the simplest screening tool.

The Endocrine Society recommends that any testosterone replacement in delayed puberty start at low doses (approximately 25% of the adult replacement dose) and escalate over several years 2. For oral TU, this might translate to 79 mg twice daily as a starting point, though no pharmacokinetic study has validated this dose in adolescents.

Cardiovascular Monitoring

Jatenzo carries an FDA boxed warning for blood pressure elevation. In the adult registration trial, mean systolic blood pressure increased by 3.4 mmHg from baseline at day 120, and 7.5% of patients developed new-onset hypertension during 12 months of treatment 1.

Blood Pressure in Adolescents

Adolescent blood pressure norms differ from adult thresholds. The American Academy of Pediatrics (AAP) 2017 guideline defines hypertension in children aged 13 and older as readings at or above 130/80 mmHg 4. A 3 to 5 mmHg systolic rise in a teenager with a baseline of 118/72 may not cross the diagnostic threshold but should trigger closer follow-up.

Practical Protocol

Measure blood pressure at every clinic visit (every 3 months in year one, every 6 months thereafter). If systolic pressure exceeds 130 mmHg on two or more readings taken at least one week apart, evaluate for secondary causes, assess adherence to the twice-daily dosing schedule (missed doses followed by double-dosing can cause testosterone spikes), and consider dose reduction.

Hematocrit and Polycythemia

Testosterone stimulates erythropoiesis through EPO upregulation and direct effects on marrow stem cells. In the Swerdloff trial, hematocrit above 54% occurred in 2.1% of adult patients 1. Adolescents living at high altitude or those with underlying congenital heart disease face additional polycythemia risk. Check a complete blood count (CBC) at baseline, at 3 months, at 6 months, and semiannually thereafter. If hematocrit exceeds 54%, hold therapy until the value falls below 50% 5.

Hepatic Safety

Oral testosterone formulations have historically raised liver safety concerns. The older 17-alpha-alkylated androgens (methyltestosterone, fluoxymesterone) carry well-documented hepatotoxicity, including peliosis hepatis and cholestatic jaundice 6.

Jatenzo's Distinct Metabolism

Jatenzo uses testosterone undecanoate absorbed via the intestinal lymphatic system, bypassing first-pass hepatic metabolism. This route spares the liver from the high portal vein testosterone concentrations that damage hepatocytes with 17-alpha-alkylated compounds. In the adult trial, liver enzyme elevations above 3 times the upper limit of normal occurred in fewer than 1% of participants 1.

Adolescent Liver Considerations

Adolescents with obesity or non-alcoholic fatty liver disease (NAFLD) may have elevated baseline transaminases. Adding oral TU to a liver already under metabolic stress requires caution even with lymphatic absorption. Check alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at baseline and at months 3, 6, and 12. An ALT rise above 5 times the upper limit of normal warrants discontinuation and hepatology referral 5.

Adolescents who take Jatenzo without food reduce lymphatic absorption significantly. The capsule label specifies administration with a meal containing at least 30% fat. Skipping meals or taking the capsule on an empty stomach shifts more drug through the portal system, which may increase hepatic exposure. Adherence counseling on meal timing is a safety measure, not just an efficacy measure.

Mental Health and Behavioral Monitoring

Testosterone acts on androgen receptors in the amygdala and prefrontal cortex, brain regions that continue maturing into the mid-20s. Exogenous androgens in adolescents can amplify mood lability, irritability, and risk-taking behavior 7.

Screening at Every Visit

The Endocrine Society recommends behavioral monitoring during testosterone induction in adolescents 2. A validated tool such as the Patient Health Questionnaire for Adolescents (PHQ-A) takes less than 3 minutes to complete and can flag depressive symptoms early. Aggression, sleep disruption, and sudden academic decline should prompt dose evaluation.

Suicidality Risk

No published data link Jatenzo specifically to suicidal ideation in adolescents. The broader anabolic steroid literature, however, documents an association between supraphysiologic androgen exposure and suicidal behavior, particularly during withdrawal phases 8. Clinicians should ask directly about suicidal thoughts at each follow-up and ensure families have access to crisis resources.

Distinguishing Drug Effects from Pubertal Mood Changes

Normal puberty brings mood swings, sleep-wake disruption, and identity exploration. Separating these from drug-induced behavioral changes is difficult. A baseline behavioral assessment before starting therapy provides a reference point. Documenting mood and behavior patterns in a patient diary can help clinicians distinguish treatment effects from developmental shifts.

Reproductive and Endocrine Considerations

Exogenous testosterone suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through negative feedback on the hypothalamus and pituitary. In adolescents who have not completed pubertal development, this suppression can impair spermatogenesis and testicular growth 9.

Fertility Preservation

For adolescents old enough to produce sperm (typically Tanner stage 3 or later), semen cryopreservation should be discussed before initiating testosterone replacement. The American Urological Association (AUA) 2018 guideline on male infertility emphasizes this counseling step for any male starting exogenous testosterone, regardless of age 9.

Testicular Volume Tracking

Measure testicular volume with a Prader orchidometer at baseline and every 6 months. A decline in testicular volume from baseline may signal excessive gonadotropin suppression. In cases where fertility preservation is a priority, some clinicians add low-dose human chorionic gonadotropin (hCG) to maintain intratesticular testosterone and spermatogenesis, though this approach lacks formal study with oral TU 9.

Dosing Strategies for Adolescents

No FDA-approved adolescent dosing exists. The adult starting dose is 237 mg orally twice daily.

Low-Dose Initiation

Following the Endocrine Society's graduated approach to pubertal induction 2, a reasonable off-label strategy begins at approximately 25% of the adult dose (79 mg twice daily). This is practically achieved with the lowest available capsule strength (158 mg, split into two daily administrations if formulation allows, or by prescribing the 158 mg capsule once daily). Dose increases should occur no faster than every 6 months, guided by serum testosterone trough levels, clinical response, and safety labs.

Therapeutic Drug Monitoring

Oral TU has high intra-individual pharmacokinetic variability. Trough testosterone levels drawn 8 to 12 hours after the evening dose provide the most clinically useful data point. Target the lower half of the eugonadal range (300 to 600 ng/dL) during the first year of therapy in adolescents, then adjust upward as skeletal maturity advances 5.

Timing and Food Requirements

Each dose must be taken with a meal. This is not optional. Lymphatic absorption requires dietary fat. A meal with at least 30% fat content produces peak testosterone levels 4 to 5 hours post-dose. Adolescents who skip breakfast or eat low-fat meals will experience erratic drug levels and potentially increased hepatic exposure 1.

Drug Interactions and Contraindications

Jatenzo's lymphatic absorption pathway limits cytochrome P450-mediated drug interactions, but clinicians should be aware of several considerations specific to adolescents.

Insulin and Oral Hypoglycemics

Testosterone can improve insulin sensitivity. Adolescents with type 2 diabetes or prediabetes on metformin may require glucose monitoring adjustments when testosterone is added 10.

Corticosteroids

Concurrent systemic corticosteroid use (for asthma, inflammatory bowel disease) may blunt testosterone's anabolic effects while compounding cardiovascular risk through fluid retention and hypertension. Monitor blood pressure more frequently (monthly) in adolescents on both agents.

Absolute Contraindications

Jatenzo is contraindicated in patients with breast or prostate cancer, polycythemia (hematocrit above 54% at baseline), untreated obstructive sleep apnea, and uncontrolled heart failure. Pregnancy exposure is an FDA category X risk; male adolescents living with pregnant family members should be counseled about dermal transfer risks if handling crushed or opened capsules 5.

Practical Monitoring Schedule

A structured monitoring protocol reduces risk. The table below synthesizes recommendations from the Endocrine Society, AUA, and AAP guidelines into a single adolescent-specific timeline.

| Test | Baseline | Month 3 | Month 6 | Month 12 | Every 6 mo after | |---|---|---|---|---|---| | Serum testosterone (trough) | Yes | Yes | Yes | Yes | Yes | | CBC with hematocrit | Yes | Yes | Yes | Yes | Yes | | Hepatic panel (ALT, AST) | Yes | Yes | Yes | Yes | Yes | | Lipid panel | Yes | No | Yes | Yes | Yes | | Blood pressure | Yes | Yes | Yes | Yes | Yes | | Bone age (hand-wrist X-ray) | Yes | No | Yes | No | Yes | | Testicular volume | Yes | No | Yes | Yes | Yes | | PHQ-A or behavioral screen | Yes | Yes | Yes | Yes | Yes | | PSA | Not indicated in adolescents | | | | |

This schedule requires approximately 7 to 8 clinical encounters in the first 18 months. Insurance pre-authorization for the bone age radiographs may be necessary, particularly for off-label indications.

When to Stop or Adjust Therapy

Clear stopping rules protect adolescent patients from cumulative harm.

Dose Reduction Triggers

Reduce the dose if hematocrit reaches 50 to 54%, systolic blood pressure exceeds 130 mmHg on two occasions, bone age advancement outpaces chronological age by more than 1 year per 6-month interval, or the patient reports persistent mood disturbance that correlates temporally with dose increases.

Discontinuation Triggers

Stop therapy and reassess the diagnosis if hematocrit exceeds 54%, ALT exceeds 5 times the upper limit of normal, the patient develops signs of liver injury (jaundice, right upper quadrant pain), or suicidal ideation is reported. Restart only after specialist evaluation and resolution of the triggering finding.

Testosterone trough levels below 300 ng/dL despite maximum tolerated dosing may indicate a formulation absorption problem. Confirm meal adherence before switching to an injectable formulation.